Solamargine inhibits gastric cancer progression via inactivation of STAT3/PD‑L1 signaling

Liu,Xiongxiang; Song,Lin; Liu,Wen; Liu,Bin; Liu,Lang; Su,Yao

doi:10.3892/mmr.2024.13400

Solamargine inhibits gastric cancer progression via inactivation of STAT3/PD‑L1 signaling

Authors:
- Xiongxiang Liu
- Lin Song
- Wen Liu
- Bin Liu
- Lang Liu
- Yao Su
View Affiliations

Affiliations: Department of Gastroenterology, Xiangtan Central Hospital, Xiangtan, Hunan 411100, P.R. China, Department of Gastroenterology, Xiangtan Central Hospital, Xiangtan, Hunan 411100, P.R. China
Published online on: November 19, 2024 https://doi.org/10.3892/mmr.2024.13400
Article Number: 35
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is characterized by a high mortality rate (70%) worldwide. Programmed cell death‑1 and its ligand, programmed cell death ligand 1 (PD‑L1), are vital immune checkpoints, which serve a notable role in GC. Solamargine, an extract from traditional Chinese medicine Long Kui, exerts suppressive effects on several types of cancer including cervical, lung and prostate cancer. However, the association between solamargine and PD‑L1 in GC remains unclear. Therefore, the present study aimed to investigate the underlying mechanism of solamargine on GC. Specifically, 5‑ethynyl‑2'‑deoxyuridine and Transwell assays were performed to assess GC cell proliferation, invasion and migration. Additionally, GC cells (HGC‑827 and NCI‑N87) were stimulated with 20 ng/ml recombinant human IL‑6 for 24 h, before the protein expression levels of PD‑L1 were measured using western blot analysis. Furthermore, T cell function was evaluated through incubation of Jurkat T cells with solamargine. The results demonstrated that solamargine could markedly inhibit GC cell proliferation, migration and invasion, by inhibiting STAT3 signaling. In addition, GC cell treatment with solamargine downregulated the expression of PD‑L1. Furthermore, solamargine reversed the IL‑6‑induced PD‑L1 upregulation in GC cells by downregulating STAT3 activity. Additionally, the results demonstrated that solamargine inhibited IL‑6‑induced PD‑L1 upregulation of GC cells. This suggests that solamargine exerted an immunostimulatory activity in GC. In conclusion, the present study indicated that solamargine may inhibit the progression of GC by suppressing STAT3/PD‑L1 signaling. Therefore, treatment with solamargine may serve as novel strategy for the treatment of GC.

View Figures

View References

1	Jeon M, Jang H, Jeon H, Park CG and Kim S: Long-term late effects in older gastric cancer survivors: Survival analysis using Cox hazard regression model by retrospective electronic health records. Support Care Cancer. 32:292023. View Article : Google Scholar : PubMed/NCBI
2	Sun Z, Liu Y, Deng H, Wang S, Zhang J, Xing C and Xu C: Modified Chaishao Liujunzi Decoction inhibits bile acid-induced gastric intestinal metaplasia: From network prediction to experimental verification. Aging (Albany NY). 15:13998–14018. 2023. View Article : Google Scholar : PubMed/NCBI
3	Fang S, Liu Z, Qiu Q, Tang Z, Yang Y, Kuang Z, Du X, Xiao S, Liu Y, Luo Y, et al: Diagnosing and grading gastric atrophy and intestinal metaplasia using semi-supervised deep learning on pathological images: Development and validation study. Gastric Cancer. 27:343–354. 2024. View Article : Google Scholar : PubMed/NCBI
4	Zhu Y, Huang C, Zhang C, Zhou Y, Zhao E, Zhang Y, Pan X, Huang H, Liao W and Wang X: LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation. Nat Commun. 14:81412023. View Article : Google Scholar : PubMed/NCBI
5	Pei H, Yang J, Li W, Luo X, Xu Y, Sun X, Chen Q, Zhao Q, Hou L, Tan G and Ji D: Solanum nigrum Linn: Advances in anti-cancer activity and mechanism in digestive system tumors. Med Oncol. 40:3112023. View Article : Google Scholar : PubMed/NCBI
6	Long K, Zhou H, Li Y, Liu L and Cai J: The value of chest computed tomography in evaluating lung cancer in a lobe affected by stable pulmonary tuberculosis in middle-aged and elderly patients: A preliminary study. Front Oncol. 12:8681072022. View Article : Google Scholar : PubMed/NCBI
7	Han Y, Shi J, Xu Z, Zhang Y, Cao X, Yu J, Li J and Xu S: Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. Front Pharmacol. 13:8021682022. View Article : Google Scholar : PubMed/NCBI
8	Qu X, Xie J, Zhang Y and Wang Z: Solamargine alleviates proliferation and metastasis of cervical cancer cells by blocking the CXCL3-Mediated Erk signaling pathway. Evid Based Complement Alternat Med. 2022:76347542022. View Article : Google Scholar : PubMed/NCBI
9	Ge J, Wang P, Ma H and Zhang J: Solamargine inhibits prostate cancer cell growth and enhances the therapeutic efficacy of docetaxel via Akt Signaling. J Oncol. 2022:90559542022. View Article : Google Scholar : PubMed/NCBI
10	Huang S, Sun M, Ren Y, Luo T, Wang X, Weng G and Cen D: Solamargine induces apoptosis of human renal carcinoma cells via downregulating phosphorylated STAT3 expression. Oncol Lett. 26:4932023. View Article : Google Scholar : PubMed/NCBI
11	Cha JH, Chan LC, Li CW, Hsu JL and Hung MC: Mechanisms Controlling PD-L1 expression in cancer. Mol Cell. 76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
12	Ai L, Xu A and Xu J: Roles of PD-1/PD-L1 Pathway: Signaling, cancer, and beyond. Adv Exp Med Biol. 1248:33–59. 2020. View Article : Google Scholar : PubMed/NCBI
13	Civriz AH, Teke K, Akdas EM, Dillioglugil O, Vural C and Yaprak Bayrak B: The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment. Ural Oncol. 41:486.e1–486.e13. 2023. View Article : Google Scholar : PubMed/NCBI
14	Wen J, Peng H, Wang D, Wen ZM, Liu YT, Qu J, Cui HX, Wang YY, DU YL, Wang T, et al: Lipopolysaccharides protect mesenchymal stem cell against cardiac ischemia-reperfusion injury by HMGB1/STAT3 signaling. J Geriatr Cardiol. 20:801–812. 2023. View Article : Google Scholar : PubMed/NCBI
15	Erlichman N, Meshel T, Baram T, Abu Raiya A, Horvitz T, Ben-Yaakov H and Ben-Baruch A: The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1. Cells. 12:23382023. View Article : Google Scholar : PubMed/NCBI
16	Wang R, Ye H, Yang B, Ao M, Yu X, Wu Y, Xi M and Hou M: m6A-modified circNFIX promotes ovarian cancer progression and immune escape via activating IL-6R/JAK1/STAT3 signaling by sponging miR-647. Int Immunopharmacol. 124((Pt A)): 1108792023. View Article : Google Scholar : PubMed/NCBI
17	Ye H, Yu W, Li Y, Bao X, Ni Y, Chen X, Sun Y, Chen A, Zhou W and Li J: AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3. Hum Vaccin Immunother. 19:22697902023. View Article : Google Scholar : PubMed/NCBI
18	de Carvalho T, Lara P, Jorquera-Cordero C, Aragão CFS, de Santana Oliveira A, Garcia VB, de Paiva Souza SV, Schomann T, Soares LAL, da Matta Guedes PM and de Araújo Júnior RF: Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3/NF-kB/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin, retinoic acid, and Libidibia ferrea. Biomed Pharmacother. 168:1156632023. View Article : Google Scholar : PubMed/NCBI
19	Han Y, Liu D and Li L: PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res. 10:727–742. 2020.PubMed/NCBI
20	Dermani FK, Samadi P, Rahmani G, Kohlan AK and Najafi R: PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 234:1313–1325. 2019. View Article : Google Scholar : PubMed/NCBI
21	Fan J, Fan F, He J and Sun Y: Agaricus blazei Murill extract FA-2-b-β inhibits gastric cancer cell proliferation by apoptosis by the mitochondrial pathway and blocking the cell cycle. Asian J Surg. 47:1560–1561. 2023. View Article : Google Scholar : PubMed/NCBI
22	Han EK, Woo JW, Suh KJ, Kim SH, Kim JH and Park SY: PD-L1 (SP142) expression in primary and recurrent/metastatic triple-negative breast cancers and its clinicopathological significance. Cancer Res Treat. 56:557–566. 2023. View Article : Google Scholar : PubMed/NCBI
23	Anderson HG, Takacs GP, Harris DC, Kuang Y, Harrison JK and Stepien TL: Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma. J Math Biol. 88:102023. View Article : Google Scholar : PubMed/NCBI
24	Yu P, Wei H, Li K, Zhu S, Li J, Chen C, Zhang D, Li Y, Zhu L, Yi X, et al: The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun. J Exp Clin Cancer Res. 41:3462022. View Article : Google Scholar : PubMed/NCBI
25	Liu Y, Liu X, Zhang N, Yin M, Dong J, Zeng Q, Mao G, Song D, Liu L and Deng H: Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B. 10:2299–2312. 2020. View Article : Google Scholar : PubMed/NCBI
26	Wang J, He X, Jia Z, Yan A, Xiao K, Liu S, Hou M, Long Y and Ding X: Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway. Pharm Biol. 62:33–41. 2024. View Article : Google Scholar : PubMed/NCBI
27	Li XH, Huang GZ, Xu ZL, Zhao CY, Dong XY, Cui BK and Lin XJ: IL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer. J Transl Med. 21:9112023. View Article : Google Scholar : PubMed/NCBI
28	Liu C, Shen A, Song J, Cheng L, Zhang M, Wang Y and Liu X: LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity. Cancer Commun (Lond). 44:76–100. 2024. View Article : Google Scholar : PubMed/NCBI
29	Jiang T, Xia Y, Li Y, Lu C, Lin J, Shen Y, Lv J, Xie L, Gu C, Xu Z and Wang L: TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer. Cancer Lett. 581:2165102024. View Article : Google Scholar : PubMed/NCBI
30	Wang H, Zhou Z, Zhang J, Hao T, Wang P, Wu P, Su R, Yang H, Deng G, Chen S, et al: Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer. Cancer Lett. 581:2164982024. View Article : Google Scholar : PubMed/NCBI